MEDNAX Inc (NYSE:MD) – Analysts at William Blair lowered their Q1 2018 earnings per share estimates for MEDNAX in a research report issued to clients and investors on Tuesday. William Blair analyst R. Daniels now expects that the company will post earnings per share of $0.78 for the quarter, down from their previous estimate of $0.79. William Blair also issued estimates for MEDNAX’s Q3 2018 earnings at $1.06 EPS, Q4 2018 earnings at $1.09 EPS and FY2018 earnings at $3.91 EPS.
Several other analysts have also recently issued reports on the stock. Stephens set a $62.00 price objective on shares of MEDNAX and gave the company a “buy” rating in a research note on Thursday, February 8th. Citigroup decreased their price target on shares of MEDNAX from $52.00 to $47.00 and set a “neutral” rating for the company in a research report on Friday, November 3rd. Zacks Investment Research raised shares of MEDNAX from a “hold” rating to a “buy” rating and set a $60.00 price target for the company in a research report on Tuesday, January 23rd. JPMorgan Chase & Co. upped their price target on shares of MEDNAX from $46.00 to $55.00 and gave the stock a “neutral” rating in a research report on Monday, February 12th. Finally, Jefferies Group set a $50.00 price target on shares of MEDNAX and gave the stock a “hold” rating in a research report on Tuesday, February 6th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $54.92.
MEDNAX (NYSE MD) opened at $57.35 on Thursday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.18 and a current ratio of 1.18. MEDNAX has a 12-month low of $40.56 and a 12-month high of $72.13. The stock has a market capitalization of $5,394.18, a P/E ratio of 18.32, a P/E/G ratio of 1.43 and a beta of 0.31.
MEDNAX (NYSE:MD) last announced its quarterly earnings data on Thursday, February 8th. The company reported $0.87 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.83 by $0.04. MEDNAX had a return on equity of 10.10% and a net margin of 9.26%. The company had revenue of $910.82 million for the quarter, compared to analyst estimates of $884.55 million. During the same quarter in the previous year, the company earned $1.00 EPS. The firm’s revenue for the quarter was up 9.6% compared to the same quarter last year.
Large investors have recently modified their holdings of the stock. Prudential Financial Inc. lifted its position in shares of MEDNAX by 976.9% in the 3rd quarter. Prudential Financial Inc. now owns 641,057 shares of the company’s stock valued at $27,642,000 after acquiring an additional 581,527 shares in the last quarter. Quantbot Technologies LP purchased a new stake in MEDNAX in the 3rd quarter worth approximately $695,000. Point72 Asset Management L.P. increased its stake in shares of MEDNAX by 71.7% during the 3rd quarter. Point72 Asset Management L.P. now owns 132,700 shares of the company’s stock worth $5,722,000 after purchasing an additional 55,400 shares during the last quarter. Advisor Group Inc. increased its stake in shares of MEDNAX by 41.9% during the 3rd quarter. Advisor Group Inc. now owns 8,361 shares of the company’s stock worth $359,000 after purchasing an additional 2,468 shares during the last quarter. Finally, Thompson Siegel & Walmsley LLC increased its stake in shares of MEDNAX by 19.7% during the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 2,598,925 shares of the company’s stock worth $112,065,000 after purchasing an additional 428,184 shares during the last quarter. Institutional investors and hedge funds own 95.12% of the company’s stock.
In related news, insider John C. Pepia sold 3,000 shares of the stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $51.58, for a total transaction of $154,740.00. Following the completion of the sale, the insider now directly owns 35,569 shares of the company’s stock, valued at $1,834,649.02. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 2.40% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION WARNING: “Q1 2018 EPS Estimates for MEDNAX Inc (MD) Reduced by William Blair” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/24/q1-2018-eps-estimates-for-mednax-inc-md-reduced-by-william-blair.html.
MEDNAX Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.